Farmas USA

De estas mantengo 500.000 a 0,0032... y estaba pensando en soltarlas ya... pero me estás animando a mantenerlas, jeje

No me atrevo abrir el broker ... lo hare cuando cierre el mercado .... no me fio de mi dedo ....

NVAX

Celebremos un nuevo cumple... Crece a toda pastilla...

Es normal que sea así... cada 'año' que pasa, el siguiente supone una menor subida.

De 4 a 5, +25%
De 10 a 11, +10%
De 20 a 21, +5%

NVAX

ENTA

¿Alguien la sigue? Me sorprende su bajo múltiplo (P/E 7-8), para el que no acabo de ver motivo.

DelMar's abstract entitled, "Update on Phase 1/2 study of VAL-083 (dianhydrogalactitol) in patients with recurrent malignant glioma," will be presented during a poster session at GBM2015, II International Symposium on Clinical and Basic Investigation in Glioblastoma, being held September 9 - 12, 2015, in Toledo, Spain.

This important conference gives us the opportunity to present data directly to major luminaries in the GBM field on a global stage as well as provide a deeper analysis into the data from our dose-escalation and get invaluable input from these leaders.

http://ir.delmarpharma.com/press-releases/detail/769/delmar-pharmaceuticals-to-present-updated-phase-iii

DMPI

DelMar Pharmaceuticals, Inc. is offering up to a maximum of up to 11,940,299 shares (“Maximum Shares Offering”) of our common stock together with 11,940,299 Warrants to purchase one share of our common stock for gross proceeds of $8,000,000 (the “Maximum Offering Amount”) before deduction of commissions and offering expenses. There is no minimum offering amount required as a condition to closing in this offering, and as a result, the actual public offering amount, any placement agent fees, and proceeds to us, if any, are not presently determinable and may be substantially less than the total Maximum Offering Amount. This offering will terminate on July 31, 2015, unless the offering is fully subscribed before that date or we decide to terminate the offering prior to that date. In either event, the offering may be closed without further notice to you. Any and all funds for securities purchased in the offering will be transmitted directly to us for our immediate use in our drug development and corporate activities. One share of common stock is being sold together with a Warrant. Each Warrant is immediately exercisable for one share of common stock at an exercise price of $__ per share and will expire 5 years after the issuance date. The Warrants will be issued in book-entry form.

Our common stock is quoted on the OTCQX under the symbol “DMPI”. On June 29, 2015, the last reported sale price for our common stock on the OTCQX was $0.69 per share. Subsequent to the closing of this offering and once we meet the listing requirements, we intend to apply to list our common stock on the NYSE MKT or the NASDAQ Capital Market. No assurance can be given that our application will be approved. Currently, no public market exists for our Warrants and we do not intend to apply for the listing of the Warrants on any securities exchange. The shares of common stock and the Warrants are immediately separable and will be issued separately but will be purchased together in this offering.

Enhorabuena. Espero que esas 4000 que conservas de NVAX te den mas pluses, que muchos estamos en el mismo barco

NVAX
Kiyosaki, no me extraña que semejante subida te haya confundido:))
No sé qué va a ser de nosotros cuando vayan saliendo los cuatro ases, ufff.
Buen timing para cambiar morralla por nuestra querida ¿eh? jajaja, ya no puedes decir que no estás en racha:)
Hay que poner en hora ese reloj, ahora atrasa 9 minutos:)